• registration362

Exactis Innovation Selects Ion GeneStudio S5 Systems and Oncomine Assays to Drive Canadian Clinical

At risk cancer patients across Canada may now be able to have their tumors molecularly profiled using next-generation sequencing (NGS) as part of a national effort to expedite enrollments in clinical trials. Led by Exactis Innovation, a non-profit organization focused on accelerating precision cancer research and access to targeted therapies, the program's NGS-based studies will be standardized on Thermo Fisher Scientific's Oncomine assays and Ion GeneStudio S5 Series systems.

Read the press release here.


5450 Chemin de la Côte-des-Neiges

Suite 522

Montréal, Qc

H3T 1Y6


  • White LinkedIn Icon
Send Us a Message

© 2020 by Exactis Innovation